In support of these findings, we confirmed the SUMO-1-CDK6 interaction in GBM cells and demonstrated that small molecule-mediated inhibition of SUMOylation can decrease in CDK6 levels in multiple human GBM cell lines [87]. This evidence concerns the gene CDK6 and glioblastoma.